Why Is Novocure (NVCR) Stock Down 30% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Following Novocure’s disappointing late-stage clinical trial for its cancer-treating platform, NVCR stock stumbled on relevancy concerns.

The post Why Is Novocure (NVCR) Stock Down 30% Today? appeared first on InvestorPlace.

• ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors